Intercell AG Announces Q1 2011 Results and Updates on R&D Progress

Wednesday, May 11, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

Significant increase in IXIARO®/JESPECT® sales compared to Q1 2010

Key Financial Figures

EUR in thousands

3 months endedMarch 31,

Year ended

Dec. 31,

2011

2010

2010

Revenues

5,692

4,756

34,215

Net loss

(11,257)

(14,702)

(255,182)

Net operating cash flow

(23,453)

(15,468)

(65,120)

Cash and marketable securities, end of period

87,697

158,216

86,182



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store